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Abstract: In the present study, liquid chromatography-mass spectrometry (LC-MS) was employed to
characterise the metabolic profiles of two human ovarian cancer cell lines A2780 (cisplatin-sensitive)
and A2780CR (cisplatin-resistant) in response to their exposure to melittin, a cytotoxic peptide from
bee venom. In addition, the metabolomics data were supported by application of Biolog microarray
technology to examine the utilisation of carbon sources by the two cell lines. Data extraction with
MZmine 2.14 and database searching were applied to provide metabolite lists. Principal component
analysis (PCA) gave clear separation between the cisplatin-sensitive and resistant strains and their
respective controls. The cisplatin-resistant cells were slightly more sensitive to melittin than the
sensitive cells with IC50 values of 4.5 and 6.8 µg/mL respectively, although the latter cell line
exhibited the greatest metabolic perturbation upon treatment. The changes induced by melittin in the
cisplatin-sensitive cells led mostly to reduced levels of amino acids in the proline/glutamine/arginine
pathway, as well as to decreased levels of carnitines, polyamines, adenosine triphosphate (ATP) and
nicotinamide adenine dinucleotide (NAD+). The effects on energy metabolism were supported by
the data from the Biolog assays. The lipid compositions of the two cell lines were quite different with
the A2780 cells having higher levels of several ether lipids than the A2780CR cells. Melittin also had
some effect on the lipid composition of the cells. Overall, this study suggests that melittin might have
some potential as an adjuvant therapy in cancer treatment.
Keywords: metabolomics; Melittin; LC-MS; ovarian cancer; A2780 cells; cisplatin resistance
1. Introduction
Growth of cancers is associated with various metabolic changes at the cellular level, which can be
used as biomarkers for diagnosis, prognosis and evaluation of anticancer therapies [1]. For instance,
unlike normal cells, cancer cells are more dependent on aerobic glycolysis, fatty acid synthesis,
and glutaminolysis for proliferation [2]. Thus, evaluation of the concentrations of specific metabolites
in a cell can provide insights into its metabolic state relative to the physiological norm. The metabolic
Metabolites 2016, 6, 35; doi:10.3390/metabo6040035 www.mdpi.com/journal/metabolites
Metabolites 2016, 6, 35 2 of 18
profile of cancer cells can also provide an understanding of the process of carcinogenesis and the
mechanism of chemoresistance leading to development of better diagnostic and therapeutic tools [3].
Worldwide, more than 230,000 women are diagnosed with ovarian cancer each year, and this
disease is responsible for an estimated 140,000 deaths per year [4]. Platinum (e.g., cisplatin) and
taxane (e.g., paclitaxel)-based chemotherapies are currently the first line treatments for ovarian
cancer, but relapse occurs in 70% of patients [3]. Although most ovarian cancers remain sensitive
to these therapies, there is growing resistance against them which reduces the time to disease
progression following the initial treatment, and minimises their efficacy upon further treatment
during relapse [5]. The anticancer activity of platinum arises from its ability to form irreparable
intra-strand DNA crosslinks/adducts, which leads to cell apoptosis [6], as well as induction of
oxidative and endoplasmic reticulum stress [7–9]. On the other hand, platinum resistance in cancer
results from various adaptive mechanisms including reduced cellular uptake, increased DNA repair
and tolerance [10], and inactivation by glutathione [10,11]. It has been previously reported that
platinum-sensitive (A2780) and resistant (C200) ovarian cancer cell lines have distinct metabolic
profiles in various interdependent pathways [3].
Melittin, is the main component of honey bee venom and has demonstrated a variety of biological
and pharmacological applications [12,13]. It has natural anti-bacterial, anti-viral, and anti-inflammatory
properties [12,13]. It has also been shown to have diverse anticancer effects in several different cancer
cell lines including those of gastric [14,15], breast [12,16], ovarian [16,17], liver [18,19], prostate [16],
cervical [16], and lung [20] origins. The mechanisms by which melittin, an amphipathic haemolytic
peptide, exerts its potential anticancer effects include inhibition of cell proliferation [12,17], induction of
apoptosis [12,14,15,21], and direct necrosis [14,15]. The mechanism of apoptosis appears to be related
to the activation of the caspase-dependent pathway [15,16,21]. On the other hand, necrosis arises
from damage to the cell membranes through necrotic cytotoxicity, as has been observed in rat
thymocytes, murine skeletal muscle cells, gastrointestinal (GI) tumour cells, erythrocytes, lymphocytes,
lymphoblastoid cells, rat primary alveolar cells, and intestinal Caco-2 cells [15,21]. Melittin can also
cause cell cycle arrest leading to inhibition of cell proliferation and growth. It can contribute to
inhibition of angiogenesis through its ability to suppress epidermal growth factor (EGF)-induced
vascular endothelial growth factor (VEGF) secretion and inhibit the creation of new blood vessels
by influencing hypoxia-inducible factor (HIF)-1a [22]. Previous studies on ovarian cancer cells have
shown that melittin inhibits their growth through induction of apoptosis mediated via inhibition of
signal transducer and activator of transcription 3 (STAT3) and activation of Janus kinase 2 (JAK2),
both of which are critical during angiogenesis [16]. Melittin can also prevent EGF-induced cell invasion
through its inhibition of the PI3K/Akt/mTOR signaling pathway, but this is primarily related to breast
cancer cells [12]. In hepatocellular carcinoma, melittin appears to inhibit cell proliferation through its
influence on methyl-CpG binding protein 2 (MeCP2), which is a critical element in tumour growth and
development [19]. As a consequence, melittin induces a delay in G0/G1 cell cycle progression, which it
is able to accomplish without causing apoptosis [19]. Based on these observations, it is apparent that
melittin affects cancer cells in a variety of ways that are different from those induced by platinum-based
agents. This difference in molecular action could be reflected at cellular level in terms of differences in
the metabolite profiles, and would suggest an opportunity for synergy between the two agents and a
possible lack of cross-resistance. By determining the metabolite differences between platinum-sensitive
and resistant cancer cells after treatment with melittin, it could be possible to understand the latter’s
metabolic effects on these cells in relation to their platinum chemosensitivity.
Metabolomics is a growing and powerful technology capable of detecting hundreds to thousands
of metabolites in tissues and biofluids [23–26]. With recent advances in both instrumental and
computational metabolomics technologies, it is now possible to gain deeper understanding of
the metabolic processes occurring within cancer cells, including how they exploit the process of
glycolysis. Cancer cells are known to rely on higher rates of glycolysis, an observation that is known
as the “Warburg effect”. With metabolomic profiling, it is possible to relate the “Warburg effect”
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to the production of amino acids, nucleotides, and lipids necessary for tumour proliferation and
vascularisation [27]. Some researchers have suggested that metabolic profiling can be an invaluable
tool in the evaluation of drug targets and analysis of malignant phenotypes, including the diagnosis
of cancer [28]. For instance, by comparing the metabolite profile of cancer cell lines such as ovarian
cancer cells pre- and post-treatment, it is possible to identify relevant metabolic changes that relate
to specific treatments, which not only helps in determining the efficacy of the treatment, but is also
essential in elucidating its pharmacodynamics and identifying the essential biomarkers involved. Thus,
metabolomic analysis of lysates from cell cultures has many potential applications and advantages
over conventional methods of analytical biochemistry and cell line testing. It is anticipated that as
more robust platforms for metabolomics of cell cultures become available, this will facilitate greater
understanding of drug actions both in vitro and in vivo, as well as aiding the rapid incorporation of
drug leads into novel therapeutic agents [29].
Phenotype Microarrays (PMs) use a patented redox chemistry, employing cell respiration as
a universal reporter. These assays potentially provide a natural fit to support data obtained from
metabolomics screens. The redox assay provides for both amplification and precise quantitation
of phenotypes. Redox dye mixes contain a water-soluble nontoxic tetrazolium reagent that can
be used with virtually any type of animal cell line or primary cell [30]. The dyes used in Biolog
(Hayward, CA, USA) assays measure output of nicotinamide adenine dinucleotide reduced form
(NADH) production from various catabolic pathways present in the cells being tested. If cell growth
is supported by the medium in an assay well, the actively metabolizing cells reduce the tetrazolium
dye. Reduction of the dye results in colour formation in the well, and the phenotype is considered
“positive.” If metabolism is hampered or growth is poor, then the phenotype is “weakly positive”
or “negative,” and little or no colour is formed in the well. This colorimetric redox assay allows
examination of the effect of treatment on the metabolic rate produced by different substrates and thus
is an excellent technique to combine with examination of metabolic output via metabolomics screens.
The current study sought to examine the metabolic effects of melittin on cisplatin-resistant
(A2780CR) and cisplatin-sensitive (A2780) human ovarian cancer cell lines viamass spectrometry-based
metabolic profiling in combination with Biolog microarray assays. Each of the cell lines was separately
treated with sub-lethal doses of melittin for 24 h before extraction and global metabolite analysis of
cell lysates by LC-MS using a high performance liquid chromatography (HPLC) system coupled to an
Orbitrap Exactive mass spectrometer using a ZIC-pHILIC column. The resulting data were extracted
by MZMine and subsequently analysed by univariate and multivariate approaches with SIMCA-P.
2. Results
2.1. Melittin Sensitivity of the Ovarian Cancer Cells
Figure S1 shows the cell viability plots for A2780 and A2780CR cells treated with cisplatin. Melittin
exhibited toxicity against both A2780CR and A2780 cells, with IC50 values of 4.5 and 6.8 µg/mL,
respectively (Figure 1). Thus, the cisplatin-resistant A2780CR cells were more sensitive to
melittin than the cisplatin-sensitive A2780 cells and exhibited a response curve suggestive of a
dose-response relationship.
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Figure 1. Effect of melittin on the viability of the ovarian cancer cells A2780 and A2780CR. Cell viability
was determined following treatment with varying doses of melittin for 24 h (IC50 = 6.8 µg/mL A2780;
IC50 = 4.5 µg/mL A2780CR).
2.2. Phenotypic MicroArray (PM) Assay of Untreated and Melittin Treated A2780 and A2780CR Cells
The cells were tested by using standard protocols for metabolic phenotypemicroarray-mammalian
(PM-M) cell assays (Biolog, Hayward, CA, USA). In order to select the proper dye mix, an optimisation
experiment was performed in order to determine which of the two Biolog redox dyes (MA or MB) was
most appropriate for phenotypic microarray (PM) assay of both A2780 and A2780CR cells. Figure S2
shows the layout of the carbon sources in the PM-M1 microplate. Figure S3 shows the colours which
developed in the plates after inoculation with A2780 and A2780CR cells in the presence and absence
of melittin. Figure 2 indicates the extent of utilisation of the different carbon sources by the resistant
and sensitive cells. A number of the carbon sources were used by both cell lines. However, many of
the substrates in the microarray plate do not appear to be useful as carbon sources. There were clear
phenotypic differences and the A2780CR cells would appear to have a slightly more active glycolytic
pathway as judged by the rate of utilization of glucose and fructose phosphates, although the rates of
glucose and pyruvate utilisation were higher in the A2780 cell line. Inosine also appears to be a very
favourable carbon source and is used by the A2780CR cells to a greater extent than by the A2780 cells.
Neither Krebs cycle intermediates nor short chain fatty acids appear to be useful as carbon sources
underlining the dependence of both cell lines on glycolysis, which is generally the case in cancer cell
lines [2].
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Figure 2. Comparison of substrate metabolism in A2780 and A2780CR. Dye reduction rates calculated
following 24 h incubation of cells.
Metabolites 2016, 6, 35 5 of 18
Treatment of the cells with melittin produced a very different effect on the sensitive cells in
comparison with the resistant cells. In the resistant cells carbon metabolism was not that strongly
affected and the cells continued to produce NADH, but in the sensitive cells there was a huge reduction
in carbon metabolism (Figures 3 and 4). This suggests that there may be differences in the mechanisms
by which the two cell lines respond to melittin, which could lead to different mechanisms of cell death
induced by the treatment.
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Figure 3. Comparison of substrate metabolism in A2780 cells following melittin exposure.
Dye reduction rates calculated following 24 h incubation of cells with melittin at IC50 (6.8 µg/mL)
concentration. C = untreated controls; T = melittin treated.
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Figure 4. Comparison of substrate metabolism in A2780CR cells following melittin exposure.
Dye reduction rates calculated following 24 h incubation of cells with melittin at IC50 (4.5 µg/mL)
concentration. C = untreated controls; T = melittin treated.
2.3. Effect of Melittin on the Metabolomes of Both Cell Lines
In order to gain a better understanding of the mechanism of melittin toxicity in the two cell
lines, differences in the levels of metabolites induced by treatment with melittin at concentrations
corresponding to IC50 with respect to each cell line were assessed. PCA and HCA analyses were used
to classify the metabolic phenotypes and identify the differentiating metabolites. A clear separation
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of melittin-treated A2780 and A2780CR cells, and their respective untreated controls, was achieved
indicating unique metabolite profiles for the treated and control cells on a PCA scores plot (Figure 5).
The model parameters and validation of the plot suggested a good model (2 components, R2X = 0.814;
Q2 = 0.526). The HCA groupings of the metabolomics data showed distinct separation between the cell
lines themselves as well as between the control and treated samples of each cell line.
Figure 5. Multivariate data analysis of the ovarian cancer cells A2780 and A2780CR treated with
melittin. PCA scores plot generated from PCA using LC-MS normalised data of treated cells and
controls. MS circles: A2780-treated cells; C circles: untreated A2780 cells; MR circles: A2780CR -treated
cells; CR circles: untreated A2780CR.
Table 1 shows the metabolic differences between the sensitive and resistant cell lines. The low
levels of ATP in the A2780 cells reflected the Biolog data suggesting that these cells have reduced
rates of glycolysis in comparison with the resistant cells. Several metabolites in the TCA cycle differed
between the sensitive and resistant cells including citrate, 2-oxoglutarate, and malate. None of the TCA
intermediates supplied in the Biolog array were utilised by the cell lines as carbon sources. However,
pyruvate was used as a carbon source and presumably enters the Krebs cycle. Treatment with melittin
further reduced the levels of ATP in the A2780 cells whereas melittin had little effect on the ATP levels
in the A2780CR cells. There were marked differences in levels of some carnitines between the sensitive
and resistant cells with the sensitive cells having much higher levels of butyryl carnitine. However,
there was no evidence from the Biolog data that short chain fatty acids were utilised as carbon sources.
The most marked differences between the sensitive and resistant cells were in the polyamine
pathway where 14 metabolites in the pathway were altered in the sensitive cells in comparison with
the resistant cells. The polyamines spermidine, putrescine and N-acetylputrescine were markedly
higher in the sensitive cells and, correspondingly, many of their precursors, especially arginine, were
down regulated. Melittin treatment decreased the levels of polyamines in the sensitive cells and the
levels of arginine present in the cells were reduced almost to zero.
There were important differences in lipid composition between the two cell lines before and
after treatment with melittin. Figure 6 shows a heat map of the top 50 lipids by intensity extracted
from the A2780 cells in comparison with A2780CR cells. The top 10 most abundant lipids are similar
between the two cell lines and make up a large proportion of the lipids extracted. However, it is clear
that the A2780 cell line generally contains more lipids than the A2780CR cell line. The really marked
differences between the two cell lines are in several sphingolipids such as dehydrosphinganine and
lactosylceramide, and in some ether lipids such as PC38:4 and PC38:6, all of which are lower in the
resistant cells. The differences in lipid composition of the two cell lines suggest that either remodelling
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of the cell membrane might have occurred in order for the A2780CR cells to become resistant, or there
is decreased biosynthesis and/or increased utilisation of lipids in cisplatin resistant cells as has been
suggested by others [3]. Melittin appears to have some effect on lipid composition in the A2780 cells
with the levels of the abundant lipid PC34:1 decreasing, but the effect on this lipid in the A2780CR
cells is less marked. Overall there are many changes in lipid abundance in response to melittin but
they are generally quite small and restricted to the less abundant lipids (Table S1). The decrease in
the lipids induced by treatment with melittin is less in the case of the A2780CR cells suggesting less
membrane damage in the case of these cells.
 
Figure 6. Heat Map showing the relative abundance of lipids in A2780 (S), A2780CR (R) and melittin
treated (MS & MR) cells. Red = 5 × 107, Yellow = 8% of highest value, Blue = 0%.
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Table 1. Statistically differentiating metabolites in melittin treated and untreated A2780 and A2780CR cells.
m/z RT Metabolite Name
S/R MS/MR MR/R MS/S
p-Value Ratio p-Value Ratio p-Value Ratio p-Value Ratio
Proline/glutamate/arginine/polyamine metabolism
116.071 12.8 * Proline <0.01 0.837 <0.001 0.409 ns 1.056 <0.001 0.516
128.035 10.3 1-Pyrroline-3-hydroxy-5-carboxylate <0.05 0.839 <0.001 0.364 ns 1.114 <0.001 0.453
130.051 14.4 Glutamate-5-semialdehyde ns 0.944 <0.001 0.607 ns 1.065 <0.001 0.658
131.083 11.4 * Ornithine <0.001 4.774 <0.001 3.573 ns 1.001 <0.001 0.749
132.030 15.2 * Aspartate ns 1.091 <0.001 1.229 ns 1.055 <0.01 1.159
146.046 10.8 Glutamate <0.001 0.608 <0.001 0.113 ns 0.999 <0.001 0.187
147.076 14.9 * Glutamine <0.001 0.299 <0.001 0.503 <0.001 1.204 <0.001 1.906
173.104 24.6 * Arginine <0.001 0.155 <0.001 0.004 ns 1.023 <0.05 0.026
188.057 14.4 * N-Acetyl-L-glutamate <0.001 0.637 <0.001 0.146 <0.001 1.348 <0.001 0.313
89.107 15.4 ** Putrescine <0.001 2.339 <0.001 1.490 ns 1.051 <0.001 0.670
131.118 8.24 N-Acetylputrescine <0.001 5.175 <0.001 1.603 ns 1.021 <0.001 0.316
146.165 26.2 ** Spermidine <0.001 2.354 ns 1.150 ns 1.127 <0.001 0.550
150.058 11.4 * Methionine <0.001 0.422 <0.001 0.669 <0.01 1.127 <0.001 1.594
298.096 6.42 * 5′-Methylthioadenosine 0.003 1.92 ns 0.830 ns 0.839 <0.001 0.361
TCA cycle/glycolysis
133.014 16.4 * Malate <0.001 0.647 <0.001 0.238 <0.001 1.129 <0.001 0.418
145.014 15.9 * 2-Oxoglutarate ns 0.972 <0.001 0.173 <0.001 1.217 <0.001 0.221
191.020 18.4 * Citrate <0.001 2.207 <0.001 0.534 ns 1.098 <0.001 0.265
508.003 16.6 * ATP <0.001 0.267 <0.001 0.118 ns 0.963 <0.001 0.415
Carnitine metabolism/fatty acid metabolism
162.112 13.3 * Carnitine <0.001 0.253 <0.001 0.164 ns 1.065 <0.001 0.676
204.123 11.0 * Acetylcarnitine <0.001 0.273 <0.001 0.050 ns 1.016 <0.001 0.190
232.154 8.7 Butanoylcarnitine <0.001 14.083 ns 1.992 ns 0.903 <0.001 0.131
664.117 14.3 * NAD+ <0.001 0.487 <0.001 0.135 <0.001 1.228 <0.001 0.336
Miscellaneous
104.106 19.6 * Choline <0.001 0.019 <0.001 0.231 <0.001 1.423 <0.001 7.270
166.086 10.0 * Phenylalanine <0.001 0.381 <0.05 0.873 <0.01 1.157 <0.001 2.358
118.086 12.4 * Valine <0.001 1.148 <0.01 2.257 <0.01 1.148 <0.001 2.257
120.065 14.3 * Threonine <0.001 0.610 ns 0.948 <0.05 1.140 <0.001 1.704
88.040 14.7 * Alanine ns 0.965 <0.001 0.385 ns 1.098 <0.001 0.442
179.056 17.1 * Hexose <0.001 0.564 <0.001 0.364 <0.01 0.931 <0.001 0.605
195.051 13.7 * Gluconic acid <0.001 0.559 <0.001 0.103 <0.001 0.837 <0.001 0.154
258.110 14.4 * Glycerophosphocholine <0.001 0.020 <0.001 0.031 <0.001 1.529 <0.001 2.342
RT: retention time (in min); MR: melittin treated A2780CR cells; R: untreated A2780CR cells; MS: melittin treated A2780 cells; S: untreated A2780 cells; ns: non-significant.
* Retention time matches standard on ZIC-pHILIC column; ** Retention time matches standard on ZIC-HILIC column.
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2.4. Assessment of Necrotic and Apoptotic Cell Death in A2780 and A2780CR Cells
LDH (lactate dehydrogenase) release in the medium is an enzymatic indicator that illustrates the
breakdown of membrane integrity, apoptosis, or necrosis of a cell. A2780 and A2780CR cancer
cells were incubated with increasing concentrations of melittin for 24 h and intracellular LDH
release increased as a result of the breakdown of the cell or plasma membrane. The results suggest
that compared to control cells (untreated cells), melittin produced an increase in LDH leakage
when incubated with ovarian cancer cells at levels ≥6 µg/mL (Figure S4); the amount of LDH
released appeared to be concentration-dependent in A2780, but not in A2780CR, cells. However,
in comparison to staurosoporine, melittin did not induce high levels of caspase activity particularly at
6 h (Figure S5). This suggests that the mechanism of cell death promoted by melittin was via necrosis
rather than apoptosis.
3. Discussion
In this study, untargeted metabolomics was performed in order to determine the effects of
melittin on the metabolic output of A2780 and A2780CR ovarian cancer cell lines. The altered
metabolites in both cells encompassed several pathways including those of lipid, amino acid, energy,
and carbohydrate metabolism. In a previous study it was found that docetaxel, the chemotherapeutic
agent used for treatment of ovarian cancer, caused significant metabolic changes in amino acid and
carbohydrate metabolism in ovarian cancer cells (OVCAR-3) [31]. In addition, recent metabolomics
based studies in ovarian cancer cells have demonstrated that gossypol decreases cellular levels of
glutathione (GSH), aspartic acid, and flavin adenine dinucleotide (FAD) [32]. Thus, the results
obtained with melittin in this study add to the growing body of evidence regarding the utility of
metabolomics as a tool for evaluating metabolic alterations in cancer cells induced by various agents.
However, while there have been some previous metabolomics studies on the comparison between
platinum-sensitive and resistant ovarian cancer cell lines [3], and between effects of nicotinamide
phosphoribosyltransferase on ovarian and colorectal cancers [33], this is the first metabolomics-based
study to evaluate the effects of melittin on human ovarian cancer cell lines as a potential anticancer
therapeutic agent.
The overall impression is that the cisplatin-sensitive cells exhibit a much stronger metabolic
response to melittin treatment than the resistant cells, possibly indicating a greater capacity of the
former cell line to neutralise the effects of melittin given its higher IC50 value against this cell line.
In particular, the levels of several amino acids including proline, pyrroline-3-hydroxy-5-carboxylate,
glutamate, glutamate-5-semialdehyde, N-acetyl-L-glutamate, and arginine were all markedly
decreased in A2780 cells following melittin exposure. In a previous study by Poisson et al. (2015) to
compare the metabolic profiles of untreated cisplatin-resistant and sensitive cell lines [3], arginine was
found to be significantly higher in the latter. In contrast, our study shows that arginine was higher
in the resistant compared to sensitive cell lines both pre- and post-treatment with melittin. However,
it should be noted that the Poisson et al. study [3] compared the sensitive A2780 cells with C200,
a different cisplatin resistant cell line from the one used in the current study. Thus, our findings
suggest that the A2780CR cell line contains more arginine than both the cisplatin sensitive A2780 and
cisplatin-resistant C200 cell lines and, unlike in A2780 cells where it is lowered, the arginine level
in A2780CR cells is unperturbed by treatment with melittin. In correspondence to lower levels of
intermediates in the arginine pathway, ornithine, putrescine, N-acetylputrescine and spermidine were
all upregulated suggesting that the levels of arginine and its precursors are lower in the A2780 cells
since they are being directed towards polyamine biosynthesis. The lower level of methionine in these
cells correlates with an increased requirement for it in the biosynthesis of spermidine. High levels
of polyamines have been linked to high rates of cell proliferation. Treatment of the sensitive cells
with melittin results in an almost complete depletion of arginine within the cells and further lowering
of arginine precursors. The lack of arginine as a precursor appears to result in a fall in the level
of ornithine and polyamines within the cells although the levels still remain higher than those in
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the resistant cells and methionine is higher after treatment suggesting that the requirement for it in
spermidine biosynthesis is reduced because of the depletion of spermidine. Polyamine metabolism in
the resistant cells remains unaffected by melittin. Polyamines are known to act to stabilise membranes
through interaction with phospholipid head groups [34]. It has been speculated that polyamines
stabilise membrane flow, which involves fusion between the plasma membrane and Golgi derived
vesicles [35,36]. The resistant cells contain higher levels of arginine and lower levels of polyamines
suggesting a slower rate of biosynthesis of polyamines from arginine in these cells. Treatment of the
resistant cells with melittin does not affect the levels of either the polyamines or arginine to any great
extent. If the hypothesis regarding the role of polyamines in stabilising membrane flow is true, then it
is possible that the lower levels of polyamines might result in reduced capability in these cells to repair
membrane damage caused by melittin. In addition there is a link between polyamine depletion and the
inhibition of apoptotic cell death [37]. This further underlines possible differences in the mechanism of
cell death between these two cell lines.
The A2780 cells have lower levels of ATP both before and after melittin treatment in comparison
with the A2780CR cells. The Biolog data also indicates lower levels of glycolysis in the A2780 cells in
comparison with the A2780CR cells. Since ATP generation in cancer cells is primarily from glycolysis
as opposed to oxidative phosphorylation, even under normoxic conditions [38], the observed effect
implies that glycolysis may be a potential target for melittin as an anticancer agent. The strong
dependence of cancer cells on glycolysis could be the basis for melittin’s selective toxicity against
them [13–19]. On the other hand, levels of ATP in A2780CR cells were higher than in A2780 at the
outset and were not greatly affected by melittin treatment. The Biolog data also suggested a smaller
effect of melittin on ATP production in A2780CR cells since the production of NADH by the cells was
much less affected by melittin treatment than in the case of the A2780 cells. ATP levels have been
linked to the capability of cells to undergo apoptotic as opposed to necrotic cell death and this suggests
that the A2780CR cells may be undergoing apoptotic cell death in response to melittin whereas the
A2780 cells may be undergoing necrotic cell death. However, the effect of melittin on caspase levels
does not support this. In our study, we found that melittin inhibited glycolysis in A2780 cells by
reducing the level of NAD+, but this biomarker was increased in A2780CR cells. Cancer cells require
increased NAD+ biosynthesis to support anabolic metabolism, to sustain signalling processes including
sirtuin activity and ADP-ribosylation, and to maintain a redox balance. Accordingly, inhibitors of
nicotinamide phosphoribosyltransferase (NamPT), the enzyme that catalyses the rate-limiting step in
NAD+ biosynthesis, have been shown to possess moderate anti-tumour activity in monotherapy both
in vitro and in vivo [39]. The peptide toxin ricin was found to promote apoptosis by decreasing both
ATP and NAD levels in U937 cells [40] although it was proposed that necrotic mechanisms might also
be operating.
Levels of choline, methionine, phenylalanine, valine and threonine observed were raised in both
cell lines when treated with melittin and they were significantly higher in A2780 cells. These findings
resemble those from a previous study in which the levels of phenylalanine and methionine were
elevated in A2780 and HCT-116 (colorectal cancer) cell lines following treatment with FK866, a small
molecule inhibitor of NamPT [41]. However, the levels of metabolic intermediates of the TCA cycle,
such as citrate, 2-oxoglutarate, and malate were decreased in A2780 cells by melittin, but they were
increased in A2780CR. Some recent studies have demonstrated higher levels of TCA cycle intermediates
(including succinate, fumarate, andmalate) observed in tissue samples from ovarian carcinomawithout
treatment [42–44] and our study shows as well that there are significant differences in citrate and
malate levels in the untreated cells (negative controls) in which malate is decreased and citrate is
increased in A2780 relative to A2780CR cells respectively. However, the previously mentioned study
by Poisson et al. did not find significant differences in TCA cycle metabolites between untreated
platinum-sensitive (A2780) and resistant (C200) cells [3], suggesting that the A2780CR cell line has
relatively specific distinctions in its metabolome. Some acyl carnitines were also found to respond to
melittin treatment in A2780, but not in A2780CR cells. The dose-dependent decreases in L-carnitine,
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acetylcarnitine and butanoylcarnitine levels in A2780 cells after melittin exposure might be explained
based on cell-specific alteration of metabolic pathways. Carnitine serves an important role in the
regulation of energy production from fatty acids and glucose at the cellular level. It is involved in the
transport of long-chain fatty acids across the inner mitochondrial membrane, as well as facilitating
chain-shorted acyl group transportation from the peroxisomes, where they are produced, to the
mitochondria for further energy metabolism [45].
There are some significant differences in the lipid composition between A2780 cells and A2780CR
cells. Several sphingomyelin (SM) lipids are higher in the A2780 cells in comparison to the A2780CR
cells. This differs from previous reports of increased ceramide lipids, particularly glucosylceramides
and galactosylceramides, in multidrug resistant ovarian cancer cells [46] and breast cancer cells [47].
However, in these previous studies ceramides or glycosylceramides were measured rather than
sphingomyelin lipids. In common with Veldman et al. [46], we have observed lower levels of
lactosylceramide in the resistant cells. It has also been previously reported that ether lipids are
elevated in vinblastine-resistant human leukaemic lymphoblasts compared with sensitive cells [48],
although in the current case many ether lipids are elevated in the cisplatin-sensitive cells and lowered
in the resistant ones. Ether lipids increase membrane impermeability due to their ability to form
hydrogen bonds with cholesterol and their resistance to hydrolysis by phospholipases [48].
The presence of lower levels of many lipids in the resistant cells, particularly those lipids whose
function involves promoting membrane stability, suggests that cisplatin resistance in this cell line is
unconventional. Cisplatin, a polar drug, does not cross cell membranes by passive diffusion but via
action of organic cation transporters of which several have been identified [49]. Thus, it is possible that
cisplatin resistance could be mediated through mechanisms other than augmentation of membrane
lipids. This possibility is supported by two of our findings which suggest that melittin, an agent known
to destabilise cell membranes, was more active on the cisplatin resistant compared to cisplatin sensitive
cells, and that polyamines were higher in the sensitive cells. Both observations further illustrate the
fact that the A2780 cell line had a more stable cell membrane. Why membrane stability of the A2780
cells would make them more vulnerable to cisplatin still remains unclear.
Following treatment with melittin, lipids were significantly altered in both A2780 and A2780CR
cells although the fold changes are quite small. The observed effect was much more marked in the
cisplatin-sensitive cells, where there was a larger number of lipids significantly decreased, suggesting
that the latter undergo much more extensive membrane re-modelling in response to melittin in
comparison with the resistant cells.
4. Materials and Methods
4.1. Cell Lines and Cultures
The cisplatin-sensitive (A2780) and resistant (A2780CR) human ovarian carcinoma cells were
obtained from ECACC (Porton Down, Salisbury, UK) and maintained at 75 × 104 cells/mL in RPMI
1640 medium (Lonza, Verviers, Belgium) supplemented with 1% (v/v) L-glutamine (Invitrogen,
Paisley, UK), 100 IU/mL/100 µg/mL penicillin/streptomycin (Invitrogen, Paisley, UK), and 10% (v/v)
foetal bovine serum (FBS) (Life Technologies, Carlsbad, CA, USA). In addition, the cultures for the
A2780CR cells contained 1 µM cisplatinum (Tocris Bioscience, Bristol, UK) in the first three passages.
Sub-confluent cultures were split by trypsinisation every 4–5 days and maintained at 37 ◦C in a
humidified atmosphere saturated with 5% CO2.
4.2. Cell Viability Assay against Melittin
Melittin was purified from bee venom (supplied by Beesen Co. Ltd., Dae Jeon, Korea) by reversed
phase liquid chromatography [50] and reconstituted in sterile water to form a stock solution of
1 mg/mL before storage at −20 ◦C until required for analysis. Cell viability was assessed by an
Alamar® Blue (AB) cell viability reagent (Thermo Fisher Scientific, Loughborough, UK). Both A2780
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and A2780CR cells were seeded at 1 × 104 cells/well in 96-well plates (Corning®, Sigma-Aldrich,
Dorset, UK) and incubated at 37 ◦C and 5% CO2 in a humidified atmosphere for 24 h. After this
incubation period, the cells were treated with various concentrations of melittin ranging from 0.5 to
14 µg/mL in 100 µL of medium, and re-incubated at 37 ◦C and 5% CO2 for a further 24 h. Triton X at
1% (v/v) and cell culture media were used as positive and negative controls, respectively. After this,
AB was added at a final concentration of 10% (v/v) and the resultant mixture was incubated for a
further 4 h at 37 ◦C and 5% CO2. Then, the plates were read at an excitation wavelength of 560 nm
and the emission at 590 nm was recorded on a SpectraMax M3 microplate reader (Molecular Devices,
Sunnyvale, CA, USA). Background-corrected fluorescence readings were converted to cell viability
data for each test well by expressing them as percentages relative to the mean negative control value.
4.3. Determination of IC50
GraphPad Prism for Windows (version 5.00, GraphPad Software, San Diego, CA, USA) was
employed to produce dose-response curves by performing nonlinear regression analysis of the cell
viability data. The mean inhibitory concentration (IC50) values were calculated from at least three
measurements of independent experiments (n = 3).
4.4. Determination of Effect of Melittin on Cell Metabolomes
The A2780 and A2780CR cell lines were separately treated with melittin at concentrations of
6.8 and 4.5 µg/mL respectively for 24 h (n = 5). The cells were seeded at 75 × 104 cells/mL in T-25
cell culture flasks and incubated for 1 doubling time (48 h) before treatment with the melittin and
incubation for an additional 24 h. After the treatment, the medium was removed and the cells were
washed twice with 3 mL of phosphate-buffered saline (PBS) at 37 ◦C before lysis. Cell lysates were
prepared by extraction with ice cold methanol:acetonitrile:water (50:30:20) (1 mL per 2 × 106 cells).
Lipids were extracted with isopropanol (4 ◦C) (Sigma-Aldrich, Dorset, UK). The cells were scraped and
cell lysates mixed on a Thermo mixer at 1440 rotations per minute (r.p.m.) for 12 min at 4 ◦C, before
being centrifuged at 13,500 r.p.m. for 15 min at 0 ◦C. The supernatants were collected and transferred
into HPLC vials for LC-MS analysis. During the analysis, the temperature of the autosampler was
maintained at 4 ◦C. Mixtures of authentic standard metabolites (Sigma-Aldrich, Dorset, UK), prepared
as previously described [51], and the pooled quality control (QC) sample, were injected in each analysis
run in order to facilitate identification and to evaluate the stability and reproducibility of the analytical
method, respectively. The pooled QC sample was obtained by taking equal aliquots from all the
samples and placing them into the same HPLC vial.
4.5. Optimisation of Phenotype Microarray Experiment Parameters
(1) A2780 and A2780CR cells were cultured in a 75 cm2 culture flask containing 10 ml RPMI-1640
medium lacking phenol red but containing 5% (v/v) FBS, L-glutamine and Pen/Strep (Gibco™
by Life Technologies, Paisley, UK).
(2) The medium was removed from the culture flask and saved in a 15 mL sterile conical tube.
The remaining medium was aspirated and discarded from the culture flask. The adherent cells
were washed twice with 10 mL of Dulbecco’s Phosphate-Buffered Saline (D-PBS) (Gibco, Paisley,
UK) and any remaining D-PBS was aspirated and discarded.
(3) The cells were then detached by adding 2 mL of 0.25 % (v/v) Trypsin-EDTA (Gibco, Paisley, UK)
and incubated at 37 ◦C for 3 min.
(4) Then, 3 mL of culture medium was taken from the 15 mL conical tube was added to quench the
detachment reaction and the cell suspension mixed by gently pipetting up and down several
times to disperse the cells.
(5) The cells were harvested by transferring the cell suspension to the 15 mL conical tube containing
the culture medium and centrifuged at 350× g for 5 min. After centrifugation, the medium was
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aspirated and 10 mL of D-PBS was added. After that, the cell pellet was suspended in the D-PBS
by pipetting up and down several times, then centrifuged again at 350× g for 5 min.
(6) After the second centrifugation, the medium was aspirated and 10 mL of pre-warmed MC-0 was
added. The cell pellet in the MC-0 Assay Medium was suspended by pipetting up and down
several times. The MC-0 medium was composed of IF-M1 (Technopath Distribution, Tipperary,
Ireland) medium supplemented with 5.3% (v/v) dialysed foetal bovine serum (dFBS) (Gibco™ by
Life Technologies, Paisley, UK), 1.1% of 100× Pen/Strep solution (Gibco™ by Life Technologies,
Paisley, UK), and 0.16% (v/v) of 200 mM glutamine (final concentration 0.3 mM).
(7) The cell number was determined and cell viability was assessed by trypan blue dye exclusion
(Sigma-Aldrich, Dorset, UK).
(8) The cells were suspended in enough MC-0 Assay Medium to fill the selected number of PM
panels and to achieve a density of 4 × 105 cells/mL.
(9) After that, 50 µL/well of the cell suspension was added on two sets of PM-M1 plates (Technopath
Distribution, Tipperary, Ireland) so that each well had 20,000 cells. The first one was used as the
control set, where untreated A2780 and A2780CR were cultured. A2780 and A2780CR seeded
in the second set of plates were exposed to melittin. Both sets of PMs containing A2780 and
A2780CR were first incubated for 24 h to allow cells to catabolise all nutrients in medium MC-0.
The treated cells set was subsequently inoculated with 25 µL of Melittin/well of three PM-M1
plates at IC50 concentration, while 25 µL of MC-0 medium was added to each well in the control
set of three PM-M1 plates.
(10) Then, the PM plates were incubated at 37 ◦C in a humidified atmosphere with 95% Air-5% CO2
for 18 h, after which the Biolog Redox Dye Mix MA was added to all wells (15 µL/well to the
plate). The plate was sealed with tape to prevent off-gassing of CO2.
(11) The plates were incubated for an additional 6 h with Biolog Redox Dye Mix MA
(Technopath Distribution, Tipperary, Ireland).
(12) Tetrazolium reduction was determined with a microplate reader (SpectraMax M3, Molecular
Devices, Sunnyvale, CA, USA). The endpoint read was performed at 590 nm with subtraction of
a 750 nm reference reading (A590-750) which corrects for any background light scattering.
4.6. LC-MS Conditions
Liquid chromatographic separation was carried out on an Accela HPLC system interfaced to an
Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) using a hydrophilic
interaction liquid chromatography (HILIC) column (ZICp-HILIC, 150 × 4.6 mm, 5 µm particle size)
supplied by Hichrom Ltd. (Reading, UK). Since chromatographic separation of polyamines is poor
on a ZIC-pHILIC column [51], a ZIC-HILIC column (150 × 4.6 mm, 5 µm particle size), supplied by
Hichrom Ltd. (Reading, UK) was employed for the determination of putrescine and spermidine in the
samples. The mobile phase for ZIC-pHILIC consisted of 20 mM ammonium carbonate (Sigma-Aldrich,
Dorset, UK) in water purified by Direct-Q 3 Ultrapure water purification system (Millipore, Watford,
UK) at pH 9.2 (solvent A) and acetonitrile (Sigma-Aldrich, Dorset, UK) (solvent B) at a flow rate of
0.3 mL/min. The elution gradient was an A:B ratio of 20:80 at 0 min, 80:20 at 30 min, 92:8 at 35 min and
finally 20:80 at 45 min as described previously [52]. In the case of the ZIC-HILIC column, the mobile
phase was 0.1% (v/v) formic acid in water (A) and 0.1% (v/v) formic acid in acetonitrile (B) with a
gradient of A:B 50:50 at 0 min, 95:5 from 20–30 min, and 50:50 from 31–36 min. The nitrogen sheath
and auxiliary gas flow rates were maintained at 50 and 17 mL/min. The electrospray ionisation (ESI)
interface was operated in a positive/negative dual polarity mode. The spray voltage was 4.5 kV for
positive mode and 4.0 kV for negative mode, while the ion transfer capillary temperature was 275 ◦C.
Full scan data were obtained in the mass-to-charge ratio (m/z) range of 75 to 1200 for both ionisation
modes with settings of AGC target and resolution as Balanced (1E6) and High (50,000) respectively.
Mass calibration was performed for both positive and negative ESI polarities before the analysis using
the standard Thermo Calmix solution (Thermo Fisher Scientific, Bremen, Germany) with additional
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coverage of the lower mass range with signals at m/z 83.0604 (2 × ACN + H) for the positive and m/z
91.0037 (2 × HCOO−) for the negative modes respectively. The resulting data were recorded using the
XCalibur 2.1.0 software package (Thermo Fisher Scientific, Bremen, Germany). Analysis of lipids was
carried out on an ACE silica gel column (150 × 4.6 mm, 3 µm, Hichrom, Reading, UK) as described
previously [52].
4.7. Data Extraction and Analysis
Data extraction for each of the samples was carried out by MZmine-2.10 software [53,54].
The extracted ions, with their corresponding m/z values and retention times, were pasted into an Excel
macro of the most common metabolites prepared in–house to facilitate identification, and a library
search was also carried out against accurate mass data of the metabolites in the Human Metabolome,
KEGG, and Metlin databases. The lists of the metabolites obtained from these searches were then
carefully evaluated manually by considering the quality of their peaks and their retention time match
with the standard metabolite mixtures run in the same sequence. All metabolites were within 3 ppm
of their exact masses. Statistical analyses were performed using both univariate and multivariate
approaches. The p-values from univariate analyses were adjusted using the Bonferroni correction
and differences in the levels (or peak areas) of the metabolites between treated and control cells were
considered significant at p < 0.05. SIMCA-P software version 14.0 (Umetrics, Crewe, UK) was used
for unsupervised multivariate analysis of the metabolite data with Pareto scaling prior to principal
component (PCA) and hierarchical clustering (HCA) analyses.
4.8. LDH Assay
The cytotoxicity of the melittin was determined by the lactate dehydrogenase (LDH) release assay
on A2780 and A2780CR cells. LDH release into the medium is due to the loss of membrane integrity
either due to apoptosis or necrosis. Briefly, A2780 and A2780CR cells were seeded at 1 × 104 cells/well
in 96-well plates and incubated at 37 ◦C and 5% CO2 in a humidified atmosphere for 24 h. The cells
were treated with different concentrations of the melittin for 24 h. Then, the supernatant (50 µL) of
the treated cells was transferred into 96-well flat-bottomed plates, and 50 µL of the LDH reaction
mix (Lactate Dehydrogenase Activity Assay Kit, MAK066, Sigma-Aldrich, Dorset, UK) was added
for 30 min. Finally, the intensity of orange colour in the samples indicating the LDH activity was
measured at 490 nm. LDH release increased in a dose-dependent manner in melittin treated A2780
and A2780CR cells compared with untreated cells. The values are represented as the means ± SD of
three separated experiments.
4.9. Caspase Activity Assay
Fluorometric assays of caspase activity were carried out by using the substrate Ac-DEVD-AMC
(BD Pharmingen, San Diego, CA, USA) for caspase-3. Both A2780 and A2780CR cells were seeded at
1 × 104 cells/well in costar 96-well black plates and incubated at 37 ◦C and 5% CO2 in a humidified
atmosphere for 24 h. Then, the cells were treated for 6 and 24 h with different concentrations of melittin
to measure caspase-3 activity. Staurosporine (Sigma-Aldrich, Dorset, UK) was used to induce apoptosis
at a concentration of 10 µM. The control cells were treated with media alone. The caspase-3 assay
buffer was prepared as described previously [55]. The caspase-3 assay buffer (3×) was added to each
well and incubated at 37 ◦C in 5% CO2 for 1 h. Fluorescence was measured at 360 nm (excitation) and
460 nm (emission) using a Spectramax M3 microplate reader. The average fluorescence values of the
background were subtracted from the fluorescence values of experimental wells. Statistical analysis
was done using one-way ANOVA followed by Bonferroni’s Multiple Comparison test.
5. Conclusions
In conclusion, this study shows that the cisplatin sensitive A2780 cells contain relatively higher
levels of ether lipids and polyamines, which might result in increased membrane stability and
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repair and thus resistance to the lytic action of melittin in comparison with the cisplatin resistant
A2780CR cells. After exposure to melittin, the levels of most of the significantly altered metabolites,
particularly amino acids and TCA cycle intermediates, were lower in A2780 compared to A2780CR
cells, suggesting different metabolic responses in the two cell lines. The large increases in choline
and glycerophosphocholine in A2780 cells may be related to increased de novo lipid synthesis and
re-direction of cellular metabolism. Thus, analysis of the full lipidome could offer a more valuable
insight. Given that melittin interacts with cell membranes, the observed effects might suggest that the
membranes are less adaptable in the cisplatin resistant cells compared to the sensitive ones. Over all,
this study shows that a LC-MS based metabolomics approach for the assessment of drug effects in vitro
provides a powerful tool for obtaining insights into the mechanism of action of potential therapeutic
agents, while offering the possibility to identify key metabolite markers for in vivo monitoring of
tumour responsiveness to standard chemotherapy. Melittin might serve as a valuable adjuvant in
cancer chemotherapy for overcoming chemoresistance.
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(B) IC50 = 4.9 µg/mL A2780. Figure S2: Layout of carbon sources in the wells on the PM-M1 microplate, Figure S3:
Changes in the metabolism of ovarian cancer A2780 and A2780CR cells, Figure S4: Lactate dehydrogenase (LDH)
assay, Figure S5: Effect of Melittin on caspase-3 activity in A2780 and A2780CR cells.
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